GlassScriptPhysician profile
Philip Andrew Doyle
NPI 1376928309
$1,365.18
in general payments reported to CMS, 2019-2025
13 companies · $1,365 in 2025
The $1,365 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,200.19 |
| Education | $164.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $376.51 | 2025 | Breztri, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $242.77 | 2025 | Nucala, Trelegy Ellipta |
| Astellas Pharma US INC | $185.65 | 2025 | Cresemba |
| Amgen INC. | $91.20 | 2025 | Tezspire |
| United Therapeutics Corporation | $90.95 | 2025 | Tyvaso, Orenitram |
| Insmed, INC. | $90.94 | 2025 | Arikayce |
| Merck Sharp & Dohme LLC | $60.57 | 2025 | Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.00 | 2025 | Ofev |
| Verona Pharma, INC. | $57.51 | 2025 | Ohtuvayre |
| Electromed, INC. | $30.89 | 2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $30.46 | 2025 | Opsumit |
| Regeneron Healthcare Solutions, INC. | $24.04 | 2025 | Dupixent |
| Baxter Healthcare | $23.69 | 2025 | Hillrom - Vest System Model 105 Home Care |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.